Sore Breasts on Wegovy: What's Happening and What to Do

Is Wegovy directly causing your breast soreness?

Semaglutide works by activating GLP-1 receptors that regulate appetite and slow gastric emptying, and the NHS patient information for semaglutide lists a recognised side-effect profile that is led by gastrointestinal symptoms: nausea, vomiting, diarrhoea, constipation, and indigestion top the list. Breast tenderness does not appear there as a common or uncommon effect.

That does not mean it cannot happen. Post-marketing reports and online accounts from patients do describe breast soreness, particularly in the weeks after starting treatment or after a dose increase. The more likely explanation in most cases is indirect rather than a direct action of the drug itself. Semaglutide changes how quickly your stomach empties, affects appetite hormones, and drives meaningful weight loss, all of which can have downstream effects on oestrogen and breast tissue. It is worth separating those pathways before drawing conclusions.

If you want to read the full side-effect picture from the licensed prescribing information, the NHS semaglutide medicines page is a clear, reliable starting point. For the broader context of what Wegovy is and how it works, our semaglutide overview covers the mechanism in plain language.

How weight loss itself can make your breasts tender

This is the factor most people overlook. Breast tissue contains a significant proportion of fat, and as body weight changes, so does the composition and sensitivity of that tissue. More importantly, fat cells produce and store oestrogen. When adipose tissue decreases (even by a few kilograms over a few weeks) circulating oestrogen levels can shift, and breast tissue is highly responsive to those shifts.

The pattern is similar to what some people notice during other periods of hormonal fluctuation: early pregnancy, starting or stopping hormonal contraception, or the perimenopause. None of those involve semaglutide, but the breast tissue response to oestrogen changes is the same underlying biology.

Rapid changes tend to produce more noticeable symptoms than gradual ones. Wegovy is designed to produce meaningful weight loss over months, and the early weeks of treatment, when appetite suppression is often strongest, can involve the fastest rate of change. That timing coincides with when breast tenderness is most commonly reported.

If you are also experiencing other localised skin or tissue discomfort at the injection site or elsewhere, it is worth noting those separately when you speak to your prescriber, so the full picture is clear.

The contraceptive pill connection, a practical thing to check

One mechanism that is well-evidenced and clinically important: GLP-1 medicines slow the rate at which the stomach empties its contents into the small intestine. For most medicines this has little consequence. For oral hormonal contraceptives, however, the timing and extent of absorption can matter.

NHS guidance specifically notes that women taking the oral contraceptive pill alongside tirzepatide (Mounjaro) should use an additional non-oral method of contraception for the first four weeks of treatment and for four weeks after each dose increase, because pill absorption may be reduced. The equivalent evidence for semaglutide is less definitive, but the same mechanism is plausible, and the NHS England guidance on weight management injections recommends discussing contraception with your healthcare team before starting either medicine.

If your pill absorption has been inconsistent, oestrogen levels could fluctuate in ways that produce breast tenderness, irregular spotting, or other hormonal symptoms. Keep your pill in the same routine, many people find storing it somewhere they see it daily, like the fridge door next to a regular morning item, helps with consistency. If you have any doubt, speak to your GP about switching to a non-oral method while you are on Wegovy. Our page on breast tenderness during semaglutide treatment explores this connection in more detail.

When to act and what the decision looks like

Most breast tenderness linked to the indirect effects described above is mild and resolves within a few weeks as your body adapts to the new weight trajectory and any hormonal fluctuation settles. The decision to act comes down to a few practical questions.

First, is the tenderness generalised (both breasts, cyclical or recently-onset) or localised to one specific area? Generalised tenderness fits the hormonal picture. A persistent lump, nipple discharge, skin changes, or pain confined to one spot in one breast are reasons to contact your GP promptly, regardless of whether you are on Wegovy, those symptoms need assessment to rule out causes that have nothing to do with your medication.

Second, is it affecting daily life or your ability to continue treatment? If soreness is severe or getting worse rather than settling, your prescriber needs to know. This is exactly the kind of question that aftercare is for. You can also read about taking a break from Wegovy if you are weighing whether to pause treatment while you get clarity.

Third, could it reflect a medication interaction or absorption issue as described above? If you are on the pill, raise this with your GP or prescriber specifically. The sore muscles page and sore throat page follow similar decision-led logic for other symptoms people notice on semaglutide treatment, the pattern of asking what is causing a symptom before deciding what to do about it applies across all of them.

If you have not yet started treatment and are trying to understand whether Wegovy is right for you, a good first step is to check your eligibility with our prescribers. Every consultation at nume is reviewed by a GPhC-registered Independent Prescriber on the same day, and you can ask about any specific health questions (including concerns about breast tenderness) as part of that process.